Loading
journalsJournal
Haematologica
The European Hematology Association's open-access journal, publishing haematological malignancy research from Europe and worldwide with no paywall.
Also called: Haematologica
Overview
Haematologica is the fully open-access journal of the European Hematology Association (EHA), founded in 1920 and published by the non-profit Ferrata Storti Foundation in Pavia on behalf of the society, with no paywall. It publishes clinical and translational studies in leukaemia, lymphoma, myeloma and MDS from Europe and worldwide, together with EHA guidelines and the EHA congress abstract book. Its readers are haematologists and researchers in haematological malignancy who want European society guidance and congress abstracts freely available. A reader of OnCo would use it for EHA guidelines and for open-access blood cancer research that can be read without a subscription.
Publisher
Ferrata Storti Foundation · European Hematology Association
Scope
haematology
Website
Access model
open access
Founded
1920
ISSN
0390-6078
observational202330 citations
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)
The clinical result is in line with commercial BCMA CAR-T products, but the point of the paper is the manufacturing: an academic hospital produced its own CAR-T cells, infused them fresh and treated patients who would otherwise wait for a commercial slot. It is the evidence base for what Immix Biopharma now develops as NXC-201.
rct2020148 citations
AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes
Bortezomib should not be added to standard chemotherapy for childhood acute myeloid leukaemia; the trial's FLT3-ITD sorafenib cohorts were reported separately.
Antonio Cuneo
President of the Scientific Committee
HaematologyChronic lymphocytic leukaemiaCytogenetics
Ferrara haematologist and CLL expert who chairs GIMEMA's Scientific Committee.
Jürgen Kuball
Daily Board member, Strategic Program Cancer
HaematologyCellular immunotherapyStem cell transplantation
Utrecht haematologist and immunotherapy researcher on the daily board of UMC Utrecht's cancer programme, known for gamma-delta T cell receptor-engineered cell therapies.
Nicolaas P.M. Schaap
Chair
HaematologyStem cell transplantationCellular therapy
Radboudumc haematologist who chairs HOVON, the Dutch-Belgian haemato-oncology cooperative group.
Polina Stepensky
Director, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center
Haematopoietic stem cell transplantationAcademic CAR-T manufactureMultiple myeloma
Runs a hospital department that makes its own CAR-T cells and gives them fresh, without freezing, at a fraction of what a commercial product costs.
Richard Van Etten
Director, Chao Family Comprehensive Cancer Center, University of California, Irvine
Haematological malignanciesLeukaemia biologyCancer centre leadership
Physician-scientist who directs the Chao Family Comprehensive Cancer Center at UC Irvine, the NCI-designated comprehensive cancer centre for Orange County.
Sirpa Leppä
Chairperson, Nordic Lymphoma Group
LymphomaMedical oncologyClinical trials
Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries.
Steven Le Gouill
Director, Institut Curie Hospital Group; haematologist
LymphomaMantle cell lymphomaHospital leadership
Steven Le Gouill is a lymphoma specialist who leads the Institut Curie hospitals.
observationalHaematologica 202330 citations
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)
The clinical result is in line with commercial BCMA CAR-T products, but the point of the paper is the manufacturing: an academic hospital produced its own CAR-T cells, infused them fresh and treated patients who would otherwise wait for a commercial slot. It is the evidence base for what Immix Biopharma now develops as NXC-201.
rctHaematologica 2020148 citations
AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes
Bortezomib should not be added to standard chemotherapy for childhood acute myeloid leukaemia; the trial's FLT3-ITD sorafenib cohorts were reported separately.
Similar pages
- CompanyGIMEMA
Shares Antonio Cuneo, European Hematology Association, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- CompanyHOVON
Shares Nicolaas P.M. Schaap, European Hematology Association, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- CompanyNordic Lymphoma Group
Shares Sirpa Leppä, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma.
- InstitutionChao Family Comprehensive Cancer Center, UC Irvine
Shares Richard Van Etten, Acute myeloid leukaemia.
- InstitutionAmerican Society of Hematology
Shares European Hematology Association, Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma.
- PersonBrian Huntly
Shares European Hematology Association, Acute myeloid leukaemia.
- PersonKonstanze Döhner
Shares European Hematology Association, Acute myeloid leukaemia.
- TrialAAML1031
Shares AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes, Acute myeloid leukaemia.